Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?

Cancer

Volumn 104, Issue 2, 2005, Pages 299-304

  Andrews, Stephen F ^a   Horwitz, Eric M ^a   Feigenberg, Steven J ^a   Eisenberg, Debra F ^a   Hanlon, Alexandra L ^a   Uzzo, Robert G ^a   Pollack, Alan ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Prostate carcinoma; Radiation therapy; Treatment delay

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; BIOCHEMISTRY; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL FEATURE; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT SCHEDULING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; RADIATION DOSE; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; BIOPSY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 22244443793     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21184     Document Type: Article

References (28)

1. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280: 969-974.
2. Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002;20:3376-3385.
3. Mackillop WJ, Fu H, Quirt CF, et al. Waiting for radiotherapy in Ontario. Int J Radiat Oncol Biol Phys. 1994;30:221-228.
4. Waaijer A, Terhaard CH, Dehnad H, et al. Waiting times for radiotherapy: consequences of volume increase for the TCP in oropharyngeal carcinoma. Radiother Oncol. 2003;66:271-276.
5. Wyatt RM, Beddoe AH, Dale RG. The effects of delays in radiotherapy treatment on tumour control. Phys Med Biol. 2003;48:139-155.
6. Huang J, Barbera L, Brouvvers M, et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol. 2003;21:555-563.
7. Richards MA, Westcombe AM, Love SB, et al. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet. 1999;353:1119-1126.
8. Fortin A, Bairati I, Albert M, et al. Effect of treatment delay on outcome of patients with early-stage head-and-neck carcinoma receiving radical radiotherapy. Int J Radiat Oncol Biol Phys. 2002;52:929-936.
9. Do V, Gebski V, Barton MB. The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol. 2000;57: 131-136.
10. Barton MB, Morgan G, Smee R, et al. Does waiting time affect the outcome of larynx cancer treated by radiotherapy? Radiother Oncol. 1997;44:137-141.
11. Schiff PB, Harrison LB, Strong EW, et al. Impact of the time interval between surgery and postoperative radiation therapy on locoregional control in advanced head and neck cancer. J Surg Oncol. 1990;43:203-208.
12. Ballo MT, Zagars GK, Cormier JN, et al. Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2004;58:1461-1467.
13. McGowan DG. The influence of treatment delay in carcinoma of the prostate treated by external beam radiation therapy [abstract]. Clin Invest Med. 2000;(Suppl) 23:E32.
14. Nguyen PL, Whittington R, Koo S. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer [abstract 4503]. In: 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 2004;22(Suppl):14S.
15. Horwitz EM, Hanlon AL, Pinover WH, et al. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma with recursive partitioning techniques. Cancer. 2001;92:1281-1287.
16. Chism DB, Hanlon AL, Horwitz EM, et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:380-385.
17. Nam RK, Jewett MA, Krahn MD, et al. Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol. 2003;10:1891-1898.
18. Moul J, Sun L, Amling C. How long can radical prostatectomy (RP) safely be delayed? CPDR's experience from 3324 cases. American Urologic Association Annual Meeting; May 8-13, 2004; San Francisco, CA (Abstract 1184). [Available from URL: http://www.urotoday.org/prod/contents/confreport/article. asp?cat=confReport&sid=184&tid=348&aid= 1354] [accessed May 4, 2005].
19. Khan MA, Mangold LA, Epstein JI, Boitnott IK, Walsh PC, Partin AW. Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol. 2004; 172(5 Pt 1):1835-1839.
20. D'Amico AV, Renshaw AA, Cote K, et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol. 2004;22:3726-3732.
21. Pollack A, Hanlon AL, Horwitz EM, et al. Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol. 2004;171:1132-1136.
22. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25-33.
23. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876-881.
24. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105.
25. Zeitman AL, Desilvio M, Slater JD. A randomized trial comparing conventional dose (70.2 GyE) and high-dose (79.2 GyE) conformai radiation in early stage adenocarcinoma of the prostate: results of an interim analysis of PROG 95-09. In: Proceedings of the 46th Annual ASTRO Meeting. Atlanta, GA. October 3-7, 2004. Abstract nr 3.
26. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103-106.
27. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21:3972-3978.
28. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937-946.